Ignite Creation Date:
2024-05-06 @ 6:53 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05815901
Status:
RECRUITING
Last Update Posted:
2023-04-18
First Post:
2023-02-27
Brief Title:
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
Sponsor:
JW Pharmaceutical
Organization:
JW Pharmaceutical
Study Overview
Official Title:
A Multi-center Randomized Double-blind Active-controlled Therapeutic Confirmatory Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EPIC
Brief Summary:
A phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None